Today, at the 5th Annual CHDI Conference on Huntington's disease, held 8 to 11 February in Palm Springs, California, NeuroSearch (NEUR.CO) presented the results from the MermaiHD study, a Phase III study with Huntexil(r) (pridopidine) for the treatment of Huntington's disease. Top-line results from the study were announced on 3 February 2010 (Announcement no. 01-10),

Presenting as the featured speaker at the conference, Dr. Joakim Tedroff, Head of Clinical Science at NeuroSearch on Wednesday 10 February, 4pm to 5pm PDT (Thursday, 1am to 2am CET) presented the study results, including the following:

* Efficacy - Results from the MermaiHD study demonstrate that six months' (26 weeks) treatment with Huntexil(R) (45 mg BID), in Huntington's patients significantly improves both voluntary movement control, as measured on the primary endpoint, the mMS, and also a broader range of voluntary and involuntary motor symptoms, including dystonia and eye movements. Measured in both the ITT (Intention to treat) and the PP (per protocol, 82% of patients) populations, the improvements seen were highly statistically significant, and thereby the results in the PP population fully confirm the ITT analysis :



 Motor scale; Significance level for the PP population; Significance level 

 for the ITT population;

 Modified Motor Score, mMS;      p